NCT06850454

Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy

A Prospective Randomized, Double-blind Controlled Trial of Olanzapine Versus Placebo in Addition to Ondansetron Plus Dexamethasone As Antiemetic Prophylaxis in Patients Receiving Moderately Emetogenic Chemotherapy

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 140 (estimated)
• Sponsor: Mahidol University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A study comparing efficacy of olanzapine versus placebo to prevent nausea and vomiting from moderate emetic risk chemotherapy

Detailed description

A randomized study comparing olanzapine versus placebo in addition to standard antiemetic regimen for preventing nausea and vomiting from moderately emetogenic chemotherapy

Conditions

• Chemotherapy Induced Nausea and Vomiting

Interventions

Type	Name	Description
DRUG	olanzapine	olanzapine 5 mg oral prior to chemotherapy on day 1 and daily on day 2-4
DRUG	Placebo	placebo 5 mg oral prior to chemotherapy on day 1 and daily on day 2-4

Timeline

• Start date: 2025-01-10
• Primary completion: 2026-01-10
• Completion: 2026-01-31
• First posted: 2025-02-27
• Last updated: 2025-02-27

Locations

1 site across 1 country: Thailand

Regulatory

• FDA-regulated drug study